ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

umeclidinium bromide

Also written as “Budesonide, Formoterol Fumarate, and Umeclidinium Bromide”, “Umeclidinium bromide 62.5mcg” and “Umeclidinium bromide 125mcg”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by 2 companies.

Drug pageUmeclidinium bromide: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 15, 20247 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only61 open or runningphase 4since Apr 15, 2024Jan 17, 2013none ahead
Chenpon Pharmaceutical10 open or runningphase 2since Aug 31, 2026Aug 31, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chenpon Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2026First study: phase 2 study in AsthmaFirst studyNCT07807007 · 150 enrolled · China

TargetBeta

CHRM3 →read by rule
“Muscarinic acetylcholine receptor M3 antagonist”ChEMBL 37, by rule

Other programs on CHRM3

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
trospiumruleBristol-Myers Squibbphase 421
trospium chlorideruleBristol-Myers Squibbphase 415
AtropineruleLaboratorios Sophia S.A de C.V.phase 317
TQC3927Sino Biopharmaceuticalphase 23
TQC3302Sino Biopharmaceuticalphase 11

Studies

The one study Chenpon Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07807007Asthma · China2CompletedAug 3, 2026150

How it is read

Names in the registry

  • “Budesonide, Formoterol Fumarate, and Umeclidinium Bromide”, 2 entries
  • “Umeclidinium bromide 62.5mcg”, 2 entries
  • “Umeclidinium bromide 125mcg”, 2 entries
  • “Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate”, 1 entry
  • “Umeclidinium bromide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.